Pay in 4 interest-free payments of $6.39 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Herold KC, Gitelman SE, Ehlers MR et al (2013) Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders
OPITAC is a tri-peptide composed of glutamic acid, cysteine, and glycine
Protocol : Dosing is typically titrated over several weeks to minimize gastrointestinal discomfort and optimize tolerance
Generally yes
Pregnant or breastfeeding women
US$ 29.36
US$ 23.32
US$ 25.41
US$ 22.00
US$ 27.78
US$ 24.76
US$ 20.65
